Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CD22 | P20273 | 4/20 | 0.34 |
| ▸ | MAG | P20916 | 4/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26156656 | 0.92 | CD22 (0.34) | LMNAKMT2ACD22MAGMETAP2 | |
| SCHEMBL25702536 | 0.90 | LMNA (0.34) | LMNAKMT2AMAGMETAP2 | |
| SCHEMBL30481196 | 0.90 | LMNA (0.34) | LMNAKMT2AMAGMETAP2 | |
| SCHEMBL13839155 | 0.88 | TNF (0.35) | KMT2ACD22MAG | |
| SCHEMBL13839174 | 0.88 | CD22 (0.34) | LMNACD22MAG | |
| SCHEMBL17300143 | 0.86 | NANP (0.37) | NANP | |
| SCHEMBL13402483 | 0.86 | LMNA (0.34) | LMNAKMT2AMAGMETAP2 | |
| SCHEMBL13949943 | 0.86 | LMNA (0.35) | LMNAKMT2AMETAP2 | |
| SCHEMBL24630164 | 0.84 | NANP (0.38) | NANP | |
| SCHEMBL15343918 | 0.84 | NANP (0.38) | NANP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | LMNA 1117/4885KMT2A 3804/4885CD22 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.